-Dragonfly Therapeutics inicia el estudio de fase 1/1b de su inmunoterapia con IL-2 en pacientes con tumores sólidos avanzados La compañÃa anuncia el primer paciente que recibe una dosis en un ensayo clÃnico de fase 1/1b que evalúa su nueva citoquina IL-2, DF6215, el séptimo fármaco…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.